These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15110527)

  • 1. Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor.
    Eichelberger MC; Prince GA; Ottolini MG
    Virology; 2004 May; 322(2):300-7. PubMed ID: 15110527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
    Ottolini M; Blanco J; Porter D; Peterson L; Curtis S; Prince G
    Pediatr Pulmonol; 2003 Oct; 36(4):290-4. PubMed ID: 12950040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.
    Matsumoto K; Ogawa N; Nerome K; Numazaki Y; Kawakami Y; Shirato K; Arakawa M; Kudoh S; Shimokata K; Nakajima S; Yamakido M; Kashiwagi S; Nagatake T
    Antivir Ther; 1999; 4(2):61-8. PubMed ID: 10682150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment.
    Fritz RS; Hayden FG; Calfee DP; Cass LM; Peng AW; Alvord WG; Strober W; Straus SE
    J Infect Dis; 1999 Sep; 180(3):586-93. PubMed ID: 10438343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors.
    Höffken G; Gillissen A
    Med Microbiol Immunol; 2002 Dec; 191(3-4):169-73. PubMed ID: 12458354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].
    de Jong JC; Beyer WE; Rimmelzwaan GF; Fouchier RA; Osterhaus AD
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):73-9. PubMed ID: 14753128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of a cross-protective immune response to influenza A in the cotton rat model.
    Straight TM; Ottolini MG; Prince GA; Eichelberger MC
    Vaccine; 2006 Sep; 24(37-39):6264-71. PubMed ID: 16860444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug under test: influenza--Relenza in daily practice. Experience during the influenza season 1999/2000.
    Schmidt RE
    Med Microbiol Immunol; 2002 Dec; 191(3-4):175-9. PubMed ID: 12458355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral neuraminidase inhibitor and an early warning system. New weapons against influenza].
    Lange W; Vogel GE
    MMW Fortschr Med; 2003 Jan; 145(3-4):36-7. PubMed ID: 12619232
    [No Abstract]   [Full Text] [Related]  

  • 11. Zanamivir: an influenza virus neuraminidase inhibitor.
    Colman PM
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):191-9. PubMed ID: 15918777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
    Wutzler P; Kossow KD; Lode H; Ruf BR; Scholz H; Vogel GE;
    J Clin Virol; 2004 Oct; 31(2):84-91. PubMed ID: 15364262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuraminidase inhibitors for treatment of influenza.
    Ebell MH
    Am Fam Physician; 2004 Jun; 69(12):2824. PubMed ID: 15222647
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
    Hurt AC; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virology. The origin and control of pandemic influenza.
    Laver G; Garman E
    Science; 2001 Sep; 293(5536):1776-7. PubMed ID: 11546857
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation.
    Johny AA; Clark A; Price N; Carrington D; Oakhill A; Marks DI
    Bone Marrow Transplant; 2002 Jan; 29(2):113-5. PubMed ID: 11850704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
    Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection.
    Herlocher ML; Truscon R; Fenton R; Klimov A; Elias S; Ohmit SE; Monto AS
    J Infect Dis; 2003 Nov; 188(9):1355-61. PubMed ID: 14593594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.